PL3186259T3 - Pochodne tetrahydronaftalenu hamujące białko mcl-1 - Google Patents
Pochodne tetrahydronaftalenu hamujące białko mcl-1Info
- Publication number
- PL3186259T3 PL3186259T3 PL15772048T PL15772048T PL3186259T3 PL 3186259 T3 PL3186259 T3 PL 3186259T3 PL 15772048 T PL15772048 T PL 15772048T PL 15772048 T PL15772048 T PL 15772048T PL 3186259 T3 PL3186259 T3 PL 3186259T3
- Authority
- PL
- Poland
- Prior art keywords
- protein
- tetrahydronaphthalene derivatives
- inhibit mcl
- mcl
- inhibit
- Prior art date
Links
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical class C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/11—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/56—Unsaturated compounds containing hydroxy or O-metal groups containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462043929P | 2014-08-29 | 2014-08-29 | |
| EP15772048.3A EP3186259B1 (en) | 2014-08-29 | 2015-08-28 | Tetrahydronaphthalene derivatives that inhibit mcl-1 protein |
| PCT/US2015/047472 WO2016033486A1 (en) | 2014-08-29 | 2015-08-28 | Tetrahydronaphthalene derivatives that inhibit mcl-1 protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3186259T3 true PL3186259T3 (pl) | 2019-04-30 |
Family
ID=54238507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15772048T PL3186259T3 (pl) | 2014-08-29 | 2015-08-28 | Pochodne tetrahydronaftalenu hamujące białko mcl-1 |
Country Status (41)
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3474B1 (ar) | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| WO2017147410A1 (en) | 2016-02-25 | 2017-08-31 | Amgen Inc. | Compounds that inhibit mcl-1 protein |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| TWI759316B (zh) | 2016-07-22 | 2022-04-01 | 法商施維雅藥廠 | Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物 |
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| SG11202001182QA (en) * | 2017-08-15 | 2020-03-30 | Abbvie Inc | Macrocyclic mcl-1 inhibitors and methods of use |
| AU2018318692A1 (en) * | 2017-08-15 | 2020-03-12 | AbbVie Deutschland GmbH & Co. KG | Macrocyclic MCL-1 inhibitors and methods of use |
| ES3036998T3 (en) | 2017-08-18 | 2025-09-26 | Amgen Inc | Compounds that inhibit mcl-1 protein |
| EP3676270A1 (en) | 2017-08-29 | 2020-07-08 | Amgen Inc. | Macrocyclic compounds that inhibit mcl-1 protein |
| US11274105B2 (en) | 2018-03-05 | 2022-03-15 | Amgen Inc. | Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists |
| CN112118845B (zh) | 2018-05-14 | 2023-06-13 | 吉利德科学公司 | Mcl-1抑制剂 |
| WO2020097577A1 (en) * | 2018-11-09 | 2020-05-14 | Prelude Therapeutics, Incorporated | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein |
| CN120698985A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| WO2020147802A1 (en) * | 2019-01-18 | 2020-07-23 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic spiroethers as mcl-1 inhibitors |
| UY38700A (es) | 2019-05-20 | 2020-12-31 | Novartis Ag | Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| US20220306653A1 (en) * | 2019-06-21 | 2022-09-29 | Janssen Pharmaceutica Nv | Macrocyclic inhibitors of mcl-1 |
| JP7295283B2 (ja) | 2019-06-25 | 2023-06-20 | ギリアード サイエンシーズ， インコーポレイテッド | Ｆｌｔ３ｌ－ｆｃ融合タンパク質及び使用方法 |
| US20240067660A1 (en) | 2019-07-09 | 2024-02-29 | Janssen Pharmaceutica Nv | Macrocyclic spirocycle derivatives as mcl-1 inhibitors |
| EP3771469A1 (en) * | 2019-07-30 | 2021-02-03 | Amgen, Inc | Formulations and dosages for administering a compound that inhibits mcl1 protein |
| WO2021047616A1 (zh) * | 2019-09-12 | 2021-03-18 | 苏州亚盛药业有限公司 | 氧氮杂环庚烷类螺环化合物、中间体及其制备方法 |
| EP4045083B1 (en) | 2019-10-18 | 2024-01-10 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| NZ786589A (en) | 2019-10-31 | 2025-03-28 | Forty Seven Llc | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| EP4054720A1 (en) * | 2019-11-04 | 2022-09-14 | Revolution Medicines, Inc. | Ras inhibitors |
| US11566007B2 (en) | 2019-11-04 | 2023-01-31 | Revolution Medicines, Inc. | Ras inhibitors |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| AU2020391106B2 (en) * | 2019-11-26 | 2024-03-21 | Gilead Sciences, Inc. | Processes and intermediates for preparing MCL1 inhibitors |
| CN117736207A (zh) | 2019-12-24 | 2024-03-22 | 卡尔那生物科学株式会社 | 二酰基甘油激酶调节化合物 |
| TWI832035B (zh) | 2020-02-14 | 2024-02-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| AU2021222332A1 (en) * | 2020-02-21 | 2022-10-20 | Janssen Pharmaceutica Nv | Macrocyclic indole derivatives as inhibitors of MCL-1 |
| JP2021161114A (ja) * | 2020-03-31 | 2021-10-11 | アムジエン・インコーポレーテツド | Ｍｃｌ−１化合物のメチル化 |
| US20230212191A1 (en) * | 2020-04-16 | 2023-07-06 | Prelude Therapeutics, Incorporated | Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein |
| MX2022013619A (es) | 2020-05-01 | 2022-11-16 | Gilead Sciences Inc | Compuestos de 2,4-dioxopirimidina que inhiben cd73. |
| CA3181189A1 (en) * | 2020-05-06 | 2021-11-11 | Amgen Inc. | Synthesis of vinylic alcohol intermediates |
| US12441681B2 (en) | 2020-05-06 | 2025-10-14 | Amgen Inc. | Synthesis of sulfonamide intermediates |
| TWI827924B (zh) * | 2020-05-06 | 2024-01-01 | 美商安進公司 | 大環Mcl-1抑制劑中間體的閉環合成 |
| AU2021268569B2 (en) * | 2020-05-06 | 2024-06-13 | Amgen Inc. | Synthesis of vinylic protected alcohol intermediates |
| TWI867217B (zh) * | 2020-05-06 | 2024-12-21 | 美商安進公司 | 乙烯基環丁基中間體之合成 |
| CN115698023A (zh) * | 2020-06-10 | 2023-02-03 | 詹森药业有限公司 | 作为mcl-1抑制剂的大环2-氨基-3-氟-丁-3-烯酰胺 |
| MX2023002691A (es) * | 2020-09-03 | 2023-05-03 | Amgen Inc | Desimetrización de diol mediante sustitución aromática nucleófila. |
| CR20230165A (es) | 2020-09-15 | 2023-06-02 | Revolution Medicines Inc | Derivados indólicos como inhibidores de ras en el tratamiento del cáncer |
| US12202782B2 (en) * | 2020-11-19 | 2025-01-21 | Gilead Sciences, Inc. | Processes and intermediates for preparing MCL1 inhibitors |
| US20240042051A1 (en) | 2020-11-24 | 2024-02-08 | Francesca Rocchetti | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| WO2022115400A1 (en) * | 2020-11-25 | 2022-06-02 | Amgen Inc. | Enantioselective alkenylation of aldehydes |
| EP4255409A1 (en) | 2020-12-07 | 2023-10-11 | Cellestia Biotech AG | Pharmaceutical combinations for treating cancer |
| EP4008324A1 (en) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer |
| ES3026771T3 (en) | 2020-12-17 | 2025-06-12 | Janssen Pharmaceutica Nv | Macrocyclic branched 3-fluoro-but-3-enamides as inhibitors of mcl-1 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| JP2024516641A (ja) | 2021-04-26 | 2024-04-16 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１阻害剤としての大環状２－アリルテトラヒドロフラン |
| CR20230558A (es) | 2021-05-05 | 2024-01-24 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cáncer |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| EP4351657A1 (en) | 2021-06-11 | 2024-04-17 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
| AU2022291381B2 (en) | 2021-06-11 | 2025-04-24 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| WO2023088894A1 (en) | 2021-11-16 | 2023-05-25 | Janssen Pharmaceutica Nv | Macrocyclic 2-amino-but-3-enamides as inhibitors of mcl-1 |
| US20230203202A1 (en) | 2021-12-08 | 2023-06-29 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| WO2023107954A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
| WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| AU2022419982A1 (en) | 2021-12-22 | 2024-06-06 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ｉｋａｒｏｓ鋅指家族降解劑及其用途 |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| WO2023196360A1 (en) | 2022-04-05 | 2023-10-12 | Amgen Inc. | Salt forms and solvates of mci-1 antagonists |
| US20240140966A1 (en) | 2022-04-05 | 2024-05-02 | Amgen Inc. | Amorphous and crystalline forms of mcl-1 antagonists |
| PE20250157A1 (es) | 2022-04-21 | 2025-01-22 | Gilead Sciences Inc | Compuestos de modulacion de kras g12d |
| CR20240553A (es) | 2022-05-20 | 2025-05-02 | Servier Lab | Conjugados de anticuerpo-fármaco de compuestos antineoplásicos y métodos de uso de los mismos |
| CN119384415A (zh) | 2022-07-01 | 2025-01-28 | 吉利德科学公司 | Cd73化合物 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| US20240254118A1 (en) | 2022-12-22 | 2024-08-01 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| KR20250167002A (ko) | 2023-04-11 | 2025-11-28 | 길리애드 사이언시즈, 인코포레이티드 | Kras 조절 화합물 |
| CN121079300A (zh) | 2023-04-21 | 2025-12-05 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| EP4516807A1 (en) | 2023-08-28 | 2025-03-05 | Consorcio Centro de Investigación Biomédica en Red | Compositions for use in a method of providing improved hematopoietic stem cell engraftment |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025111450A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd74 antibody-drug conjugates and methods of use thereof |
| WO2025111431A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd7 antibody-drug conjugates and methods of use thereof |
| WO2025126157A1 (en) | 2023-12-15 | 2025-06-19 | Advesya | Anti-il-1rap binding domains and antibody-drug conjugates thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US6042820A (en) | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
| US6472375B1 (en) | 1998-04-16 | 2002-10-29 | John Wayne Cancer Institute | DNA vaccine and methods for its use |
| ES2400371T3 (es) * | 2005-07-07 | 2013-04-09 | Abbott Laboratories | Promotores de la apoptosis |
| KR101511074B1 (ko) | 2007-04-16 | 2015-04-13 | 애브비 인코포레이티드 | 7-치환된 인돌 Ｍｃｌ-1 억제제 |
| DK2185562T3 (en) * | 2007-07-27 | 2016-02-22 | Janssen Pharmaceutica Nv | PYRROLOPYRIMIDINES SUITABLE FOR TREATING PROLIFERATIVE DISEASES |
| WO2011022312A1 (en) * | 2009-08-20 | 2011-02-24 | Merck Sharp & Dohme Corp. | Ether benzotriazole derivatives |
| KR20120060234A (ko) * | 2009-10-08 | 2012-06-11 | 샌포드-번햄 메디칼 리서치 인스티튜트 | 항암제로서의 아포고시폴론 유도체 |
| JP5937968B2 (ja) * | 2010-01-29 | 2016-06-22 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｍｃｌ‐１を調節する小分子、並びに細胞死、細胞分裂、細胞分化を調節する方法、及び疾患を治療する方法。 |
| US9486422B2 (en) | 2011-10-06 | 2016-11-08 | The Regents Of The University Of Michigan | Small molecule inhibitors of Mcl-1 and the uses of thereof |
| US9914723B2 (en) | 2012-03-29 | 2018-03-13 | The Regents Of The University Of Michigan | Small molecule inhibitors of Mcl-1 and uses thereof |
| JO3474B1 (ar) | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| WO2017147410A1 (en) | 2016-02-25 | 2017-08-31 | Amgen Inc. | Compounds that inhibit mcl-1 protein |
-
2015
- 2015-08-27 JO JOP/2015/0208A patent/JO3474B1/ar active
- 2015-08-28 TW TW104128490A patent/TWI676628B/zh active
- 2015-08-28 CA CA2959615A patent/CA2959615C/en active Active
- 2015-08-28 EA EA201790492A patent/EA031223B1/ru not_active IP Right Cessation
- 2015-08-28 SI SI201530586T patent/SI3186259T1/sl unknown
- 2015-08-28 TR TR2019/01312T patent/TR201901312T4/tr unknown
- 2015-08-28 CR CR20170116A patent/CR20170116A/es unknown
- 2015-08-28 KR KR1020177008470A patent/KR102466351B1/ko active Active
- 2015-08-28 JP JP2017511734A patent/JP6502479B2/ja active Active
- 2015-08-28 ME MEP-2019-12A patent/ME03313B/me unknown
- 2015-08-28 RS RS20190094A patent/RS58276B1/sr unknown
- 2015-08-28 TN TN2017000067A patent/TN2017000067A1/en unknown
- 2015-08-28 PT PT15772048T patent/PT3186259T/pt unknown
- 2015-08-28 AP AP2017009827A patent/AP2017009827A0/en unknown
- 2015-08-28 HR HRP20190053TT patent/HRP20190053T1/hr unknown
- 2015-08-28 LT LTEP15772048.3T patent/LT3186259T/lt unknown
- 2015-08-28 US US14/839,149 patent/US9562061B2/en active Active
- 2015-08-28 MY MYPI2017000299A patent/MY176235A/en unknown
- 2015-08-28 CN CN201580054328.4A patent/CN107001387B/zh active Active
- 2015-08-28 EP EP18187957.8A patent/EP3424931B1/en active Active
- 2015-08-28 SG SG11201701525WA patent/SG11201701525WA/en unknown
- 2015-08-28 PE PE2017000362A patent/PE20170892A1/es unknown
- 2015-08-28 ES ES18187957T patent/ES2777478T3/es active Active
- 2015-08-28 EP EP15772048.3A patent/EP3186259B1/en active Active
- 2015-08-28 PL PL15772048T patent/PL3186259T3/pl unknown
- 2015-08-28 UA UAA201702910A patent/UA118233C2/uk unknown
- 2015-08-28 SM SM20190048T patent/SMT201900048T1/it unknown
- 2015-08-28 BR BR112017004209-6A patent/BR112017004209B1/pt active IP Right Grant
- 2015-08-28 DK DK15772048.3T patent/DK3186259T3/en active
- 2015-08-28 WO PCT/US2015/047472 patent/WO2016033486A1/en not_active Ceased
- 2015-08-28 AU AU2015308735A patent/AU2015308735B2/en active Active
- 2015-08-28 ES ES15772048T patent/ES2706309T3/es active Active
- 2015-08-28 MA MA40111A patent/MA40111B1/fr unknown
- 2015-08-28 MX MX2017002656A patent/MX379155B/es unknown
- 2015-08-28 HU HUE15772048A patent/HUE041806T2/hu unknown
- 2015-08-31 UY UY0001036285A patent/UY36285A/es active IP Right Grant
- 2015-08-31 AR ARP150102791A patent/AR101729A1/es active IP Right Grant
-
2016
- 2016-12-12 US US15/376,456 patent/US10100063B2/en active Active
-
2017
- 2017-02-27 CL CL2017000469A patent/CL2017000469A1/es unknown
- 2017-02-28 IL IL250843A patent/IL250843B/en active IP Right Grant
- 2017-02-28 PH PH12017500367A patent/PH12017500367A1/en unknown
- 2017-03-10 ZA ZA2017/01763A patent/ZA201701763B/en unknown
- 2017-03-28 CO CONC2017/0002998A patent/CO2017002998A2/es unknown
-
2018
- 2018-03-07 IL IL257942A patent/IL257942B/en active IP Right Grant
- 2018-05-02 ZA ZA2018/02865A patent/ZA201802865B/en unknown
- 2018-09-05 US US16/121,750 patent/US10836779B2/en active Active
- 2018-09-06 US US16/123,030 patent/US10494381B2/en active Active
-
2019
- 2019-01-28 CY CY20191100117T patent/CY1121195T1/el unknown
- 2019-09-13 US US16/569,927 patent/US11001598B2/en active Active
-
2020
- 2020-10-21 US US17/075,864 patent/US11685747B2/en active Active
-
2023
- 2023-05-08 US US18/313,703 patent/US12024529B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201701525WA (en) | Tetrahydronaphthalene derivatives that inhibit mcl-1 protein | |
| IL269603B (en) | Compounds that inhibit mcl-1 protein | |
| PL3130671T3 (pl) | Nowa deamidaza białkowa | |
| SG11201609205WA (en) | Heterocyclyl-butanamide derivatives | |
| HUE067090T2 (hu) | Fehérje | |
| PL3418273T3 (pl) | Pochodne flawaglin | |
| HUE050450T2 (hu) | Fluoralkil-fluorén-származékok | |
| IL248773A0 (en) | History of naphthyridinedione | |
| IL248629A0 (en) | Substances containing diheteroaryl conjugated to cycloalkyl and their uses | |
| PL3099793T3 (pl) | Białko | |
| PL3119744T3 (pl) | Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu | |
| PL2902575T3 (pl) | System okuciowy | |
| GB201604125D0 (en) | Co-crystal | |
| AU2014324V (en) | MALOF002 Acmena smithii | |
| PL2899341T3 (pl) | System okuciowy | |
| GB201415235D0 (en) | Trans-locating peptide | |
| GB201404910D0 (en) | Trans-locating peptide |